# Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML

> **NCT02942758** · PHASE2 · TERMINATED · sponsor: **University Hospital Regensburg** · enrollment: 10 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** low-dose Azacitidine
- **DRUG:** Pioglitazone
- **DRUG:** ATRA
- **DRUG:** standard-dose AZA

## Key facts

- **NCT ID:** NCT02942758
- **Lead sponsor:** University Hospital Regensburg
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-10
- **Primary completion:** 2020-03-25
- **Final completion:** 2020-03-25
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Due to financial reasons.
- **Last updated:** 2024-05-08

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02942758

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02942758, "Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT02942758. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*